Review Question - QID 108947

A 69-year-old male with a history of metastatic small cell lung carcinoma on chemotherapy presents to his oncologist for a follow-up visit. He has responded well to etoposide and cisplatin with plans to undergo radiation therapy. However, he reports that he recently developed multiple “spots” all over his body. He denies any overt bleeding from his gums or joint swelling. His past medical history is notable for iron deficiency anemia, osteoarthritis, and paraneoplastic Lambert-Eaton syndrome. He has a 40 pack-year smoking history. His temperature is 98.5°F (36.9°C), blood pressure is 130/70 mmHg, pulse is 115/min, and respirations are 20/min. On examination, a rash is noted diffusely across the patient’s trunk and bilateral upper and lower extremities.

Results from a complete blood count are shown below:
Hemoglobin: 11.9 mg/dl
Hematocrit: 35%
Leukocyte count: 5,000/mm^3
Platelet count: 20,000/mm^3

The oncologist would like to continue chemotherapy but is concerned that the above results will limit the optimal dose and frequency of the regimen. A recombinant version of which of the following is most appropriate in this patient?